Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial
Alcohol and Alcoholism · 2024
DOI: 10.1093/alcalc/agae062 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alcohol and Alcoholism, 2024. Verfasst von Tracy L Simpson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Substance Addiction Treatment and Education (CESATE), Veterans Affairs (VA) Puget Sound Health Care System, 1660 So. Columbia…. Hauptthemen laut MEDLINE: Naltrexone, Prazosin, Proof of Concept Study, Alcoholism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: USAMRMC Military Operational Medicine Joint Program Committee 5 (JPC-5), Congressionally Directed Medical Research Programs.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Aims
We conducted a proof-of-concept randomized controlled trial of the mu-opioid receptor antagonist, naltrexone, augmented with the alpha-1 adrenergic receptor antagonist, prazosin, for alcohol use disorder in veterans. We sought a signal that the naltrexone plus prazosin combination regimen would be superior to naltrexone alone.
Methods
Thirty-one actively drinking veterans with alcohol use disorder were randomized 1:1:1:1 to naltrexone plus prazosin (NAL-PRAZ [n = 8]), naltrexone plus placebo (NAL-PLAC [n = 7]), prazosin plus placebo (PRAZ-PLAC [n = 7]), or placebo plus placebo (PLAC-PLAC [n = 9]) for 6 weeks. Prazosin was titrated over 2 weeks to a target dose of 4 mg QAM, 4 mg QPM, and 8 mg QHS. Naltrexone was administered at 50 mg QD. Primary outcomes were the Penn Alcohol Craving Scale (PACS), % drinking days (PDD), and % heavy drinking days (PHDD).
Results
In the NAL-PRAZ condition, % reductions from baseline for all three primary outcome measures exceeded 50% and were at least twice as large as % reductions in the NAL-PLAC condition (PACS: 57% vs. 26%; PDD: 51% vs. 22%; PHDD: 69% vs. 15%) and in the other two comparator conditions. Standardized effect sizes between NAL-PRAZ and NAL-PLAC for each primary outcome measure were >0.8. All but one participant assigned to the two prazosin containing conditions achieved the target prazosin dose of 16 mg/day and maintained that dose for the duration of the trial.
Conclusion
These results suggest that prazosin augmentation of naltrexone enhances naltrexone benefit for alcohol use disorder. These results strengthen rationale for an adequately powered definitive randomized controlled trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Excellence in Substance Addiction Treatment and Education (CESATE), Veterans Affairs (VA) Puget Sound Health Care System, 1660 So. Columbian Way, Seattle, WA 98108.
- Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, 1959 Pacific Ave, Seattle, WA 98195.
- VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 So. Columbian Way, Seattle, WA 98108.
Förderung
- USAMRMC Military Operational Medicine Joint Program Committee 5 (JPC-5)
- Congressionally Directed Medical Research Programs
Zitieren
APA
Simpson, T. L., Achtmeyer, C., Batten, L., Reoux, J., Shofer, J., Peskind, E. R., Saxon, A. J., & Raskind, M. A. (2024). Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agae062
Vancouver
Simpson TL, Achtmeyer C, Batten L, Reoux J, Shofer J, Peskind ER, et al. Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial. Alcohol and Alcoholism. 2024. doi:10.1093/alcalc/agae062
BibTeX
@article{Simpson2024,
author = {Simpson, Tracy L and Achtmeyer, Carol and Batten, Lisa and Reoux, Joseph and Shofer, Jane and Peskind, Elaine R and Saxon, Andrew J and Raskind, Murray A},
title = {Naltrexone augmented with prazosin for alcohol use disorder: results from a randomized controlled proof-of-concept trial},
journal = {Alcohol and Alcoholism},
year = {2024},
doi = {10.1093/alcalc/agae062}
}
EUVIMED